<DOC>
	<DOC>NCT00298688</DOC>
	<brief_summary>The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib</brief_summary>
	<brief_title>A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Provision of written informed consent Histologically confirmed, relapsed or refractory SCLCr Aged 18 or over and a life expectancy of more than 2 months Any evidence of clinically active interstitial lung disease Other coexisting malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>